annb0t
Top 20
Mesoblast Limited
NEW YORK, April 25, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has completed a global private placement primarily to Mesoblastâs existing major US, UK, and Australian shareholders raising approximately US$40 million, net of transaction costs, at A$0.85 per share.
Proceeds will be used to fund:
Launch and commercialization of the companyâs lead produc...
>>> Read more: Mesoblast Completes Private Placement
NEW YORK, April 25, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has completed a global private placement primarily to Mesoblastâs existing major US, UK, and Australian shareholders raising approximately US$40 million, net of transaction costs, at A$0.85 per share.
Proceeds will be used to fund:
Launch and commercialization of the companyâs lead produc...
>>> Read more: Mesoblast Completes Private Placement
